【レポートの概要（一部）】
1. Report Overview
1.1 Epigenetic Therapies, Technologies and Diagnostics: World Market Review
1.2 Global Epigenetics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Epigenetics and Uses in Pharma
2.1 How is Epigenetics Defined?
2.1.1 Epigenetic Mechanisms
2.1.2 A Brief History of Epigenetic Research
2.2 The Links between Epigenetics and Disease
2.2.1 The Role of Lifestyle in Epigenetics
2.2.2 Epigenetics and Cancer
2.2.3 Epigenetics in Inherited Disorders
2.2.4 Epigenetics in Neurological Diseases
2.3 Epigenetics in Disease Diagnosis
2.3.1 Diagnosing for Breast Cancer
2.3.2 Colorectal Cancer: The Importance of Early Diagnosis
2.3.3 Diagnostics for Lung Cancer: Difficulty in Accessing Samples
2.3.4 Diagnostics for Prostate Cancer
2.4 The Use of Epigenetics in Treating Diseases
2.4.1 DNA Methlytransferase (DNMT) Inhibitors
2.4.1.1 Myelodysplastic Syndrome (MDS)
2.4.2 Histone Deacetylase (HDAC) Inhibitors
2.4.2.1 Cutaneous T Cell Lymphoma (CTCL)
2.4.2.2 Peripheral T Cell Lymphoma (PTCL)
2.5 Drug Discovery and Development Tools Using Epigenetics
2.5.1 Bisulphite Screening for DNA Methylation
2.5.2 Chromatin Immunoprecipitation (ChIP) for Histone Modification
3. The Global Epigenetic Therapies, Technologies and Diagnostics Market 2014-2024
3.1 The Global Epigenetic Therapies, Technologies and Diagnostics Market in 2013
3.1.1 Leading Segments of the Market in 2013
3.2 The Epigenetic Therapies, Technologies and Diagnostics Global Market 2014-2024
3.2.1 The Epigenetic Therapies, Technologies and Diagnostics Global Market: Revenue Forecasts 2014-2024
3.2.2 What Will Expedite the Growth of Epigenetic Therapies, Technologies and Diagnostics Market?
3.2.3 Increase in Epigenetic Diagnostics Market Share 2014-2024
3.3 Epigenetic Therapies Submarket 2014-2024
3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2014-2024
3.3.2 Rising Importance of Epigenetic Therapies Revenue 2014-2024
3.4 Epigenetic Technologies Submarket 2014-2024
3.4.1 Epigenetic Technologies Submarket: Revenue Forecast 2014-2024
3.4.2 Epigenetic Technologies Submarket: Drivers and Restraints 2014-2024
3.5 Epigenetic Diagnostics Submarket 2014-2024
3.5.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2014-2024
3.5.2 Growth Driving Factor: New Product Launches 2014-2024
4. Leading National Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024
4.1 Leading National Markets for Epigenetic Therapies, Technologies and Diagnostics 2013
4.2 Leading National Markets: Revenue Forecasts 2014-2024
4.2.1 Global Market Will Be Dominated by the Western Countries 2014-2024
4.3 The Northern American Market 2014-2024
4.3.1 The US: The World’s Largest Market for the Epigenetic Therapies, Technologies and Diagnostics 2014-2024
4.3.2 Canada: Revenue Forecast 2014-2024
4.4 European Union (EU) Epigenetics Market: Revenues 2013
4.4.1 Leading National Markets in EU: Revenue Forecasts 2014-2024
4.4.2 Germany: Revenue Forecast 2014-2024
4.4.3 The UK: A Leading Country for Epigenetic Research
4.5 Japanese Market: Increased Interest in Epigenetics
4.6 Epigenetics in Emerging National Markets
4.6.1 BRIC Nations: Positive Growth Expected in Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024
5. Epigenetic Therapies Market 2014-2024
5.1 The Future of the Epigenetic Therapies Market 2014-2024
5.2 Vidaza (Celgene Co. / Nippon Shinyaku): The First Therapy in the Epigenetic Market
5.2.1 Vidaza: Leading Epigenetic Therapy 2004-2012
5.2.2 How Was Vidaza Affected by Patent Expiry?
5.2.3 Will Oral Azacitidine and Combination Therapy Stimulate Vidaza Growth?
5.2.4 Vidaza: Revenue Forecast 2014-2024
5.3 Dacogen (Eisai/ Janssen-Cilag/ Otsuka Pharmaceutical Co.)
5.3.1 Dacogen: Historical Revenue Performance 2006-2012
5.3.2 EU Approval and Combination Therapy to Drive Sales Growth?
5.3.3 Will Oral Azacitidine and Combination Therapy Drive Vidaza Growth?
5.3.4 Dacogen: Revenue Forecast 2014-2024
5.4 Zolinza (Merck & Co./ Taiho Pharmaceutical)
5.4.1 Zolinza for Multiple Myeloma Treatment
5.4.2 Zolinza Revenue Forecast 2014-2024
5.5 Istodax: Second Epigenetic Drug by Celgene Co.
5.5.1 Istodax: Strong Revenue Growth 2010-2011
5.5.2 International Market Approvals to Drive Growth?
5.5.3 Istodax: Revenue Forecast 2014-2024
5.6 Epigenetic Therapy Market 2013: Rich Pipeline for HDAC Inhibitors
5.6.1 Beleodaq (TopoTarget/ Spectrum Pharmaceuticals): A Novel HDAC Inhibitor
5.6.2 Faridak (Novartis): Treatment for Velcade-Refractory Multiple Myeloma
5.6.3 Entinostat (Syndax Pharmaceuticals, Inc.): Breast and Lung Cancer
5.6.4 Resminostat (4SC/ Yakult Honsha Co.): Hepatocellular Carcinoma
5.6.5 Pracinostat (MEI Pharma): Treatment for MDS and AML
5.6.6 Mocetinostat: Initiatives of Mirati Therapeutics to Drive Development
5.6.7 Quisinostat (Janssen Pharmaceutica, NV/ NewVac LLC)
5.6.8 Rocilinostat (Acetylon Pharmaceuticals): One of Celgene’s Keen Interest
5.6.9 CHR-3396 (Chroma Therapeutics)
5.6.10 Givinostat (Italfarmaco): Chronic Myeloproliferative Neoplasms and Duchenne Muscular Dystrophy
5.6.11 Shape (TetraLogic Pharmaceuticals): The First Topical HDAC inhibitor for CTCL
5.6.12 FRM-0334 (Forum Pharmaceuticals Inc): Neurodegenerative Diseases
5.6.13 4SC-202: Second Epigenetic Drug by 4SC Has Potential for Wider Indications
5.6.14 Tefinostat (Chroma Therapeutics): Haematological Cancer
5.6.15 CDX10 (Celleron Therapeutics): Part of Personalised Cancer Treatment Trial
5.6.16 RG2833 (The Scripps Research Institute): Friedreich’s Ataxia
5.6.17 Abexinostat (Pharmacyclics)
5.7 New Discoveries in the Field of HDAC 2013
5.7.1 Chemogenic Approaches to Spatiotemporal Regulation of HDAC Activity
5.7.2 Novel Lysine Pathways and Acetylation-Independent Mechanisms of HDACs
5.7.3 HDAC Inhibitor: Treatment of Pathological Muscle Remodelling
5.7.4 Design of Class I Isoform Selective Inhibitors for Use in Metabolic Indications
5.7.5 Zinc Binding Groups Inhibit Class IIa HDAC and Alters Immune Responses
5.8 DNMT Inhibitor R&D Pipeline 2013
5.8.1 SGI-110 (Otsuka Pharmaceuticals): A Second Generation DNMT Inhibitor
5.8.2 FdCyd (National Cancer Institute): Solid Tumours
5.8.3 Hydralazine: Being Tested in 23 Clinical Trials
5.8.4 MG98 (Mirati Therapeutics)
5.8.5 CP-4200: A Second Generation Vidaza
5.8.6 RX3117 (Rexahn Pharmaceuticals)
5.9 Pipeline Treatments Targeting Other Epigenetic Enzymes 2013
5.9.1 EPZ-5676 (Epizyme Inc./ Celgene Co.): The First Clinical-Stage HMT Inhibitor
5.9.2 EPZ-5676 (Epizyme Inc./ Eisai): The Second Clinical-Stage HMT Inhibitor
5.9.3 ORY-1001(Roche): Orphan Drug Status in Early Stage AML
5.9.4 SP-2528 (Salarius Pharmaceuticals)
5.9.5 RVX-208 (Resverlogix): Advancing BET Protein Inhibitors
5.10 MiRNA Therapy Pipeline 2013
5.10.1 Miravirsen (Santaris Pharma A/S): The First miRNA Therapy to Enter Human Clinical Trial
5.10.2 MRX34 (Mirna Therapeutics)
5.10.3 Collaborations of Regulus Therapeutics with Big Pharma Players
5.11 Leading Epigenetic Therapy Manufacturers and Developers
5.11.1 Celgene: Market Leader in 2013
5.11.2 Eisai
5.11.3 Janssen-Cilag
5.11.4 Otsuka Pharmaceuticals
5.11.5 Merck & Co.
5.11.6 TopoTarget to Merge with BioAlliance Pharma SA
5.11.7 Syndax Pharmaceuticals
5.11.8 4SC
5.11.9 Curis: Focusing on Multi-Targeted Treatments
5.11.10 CellCentric: Collaborating with Big Pharma for Drug Development
5.11.11 Constellation Pharmaceuticals
5.11.12 EpiTherapeutics
5.11.13 Epizyme: Signed Multiple Collaboration Agreements with Big Pharma
5.11.14 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders
5.11.15 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer
6. Epigenetic Technologies: Markets 2014-2024
6.1 Epigenetic Technologies and Services Market 2014-2024
6.1.1 Should Epigenetic Discovery and Analysis Be Outsourced?
6.2 Next Generation Sequencing (NGS)
6.2.1 Higher Speed and Reduced Costs for Epigenetic Research
6.2.2 Are Current Bioinformatic Programmes a Setback?
6.2.3 Single Molecule Sequencing to Compete with NGS
6.3 The Future of Chromatin Immunoprecipitation
6.3.1 ChIP-Seq
6.4 Future Developments in Bisulphite Screening
6.4.1 Importance of Techniques to Distinguish 5hmC
6.5 High Throughput Screening
6.6 Leading Providers of Epigenetics Technologies 2013
6.6.1 Active Motif
6.6.2 Measurement Tools for Epigenetic Research by Agilent Technologies
6.6.3 Diagenode: Best –In-Class Methyl Binding Domain Based Kit
6.6.4 DiscoveRx
6.6.5 EMD Millipore
6.6.6 Epigenetek: Specialist in Epigenetic Technologies
6.6.7 Epiontis: Assessing Purity in Regenerative Medicine Products
6.6.8 Life Technologies: Reducing NGS Process Cost
6.6.9 Qiagen: Epigenetic Technologies and Diagnostics
6.6.10 Roche
7. Epigenetic Diagnostics Market 2014-2024
7.1 Development of the Epigenetic Diagnostics Market 2014-2024
7.1.1 LDTs vs. IVDs: Two Diagnostics Development Strategies
7.2 Epigenetic Diagnostics Market 2013
7.2.1 Epi proColon 2.0 (Epigenomics)
7.2.2 ColoVantage (Quest Diagnostics)
7.2.3 Septin9 LDT (ARUP Laboratories)
7.2.4 ColoSure (LabCorp)
7.2.5 ConfirmMDx for Prostate Cancer
7.2.6 Gene Methylation in Prostate Cancer (LabCorp)
7.2.7 Epi proLung (Epigenomics)
7.2.8 MGMT Gene Methylation Assay (LabCorp)
7.2.9 PredictMDx (MDxHealth): Brain Cancer
7.2.10 Bladder Cancer Testing with CertNDx (Physician’s Choice Laboratory Services)
7.3 Epigenetic Diagnostics R&D Pipeline 2013
7.3.1 The Future of Colorectal Cancer Testing
7.3.1.1 Cologuard: Improved Sensitivity
7.3.1.2 Orion Colorectal Cancer Risk Test (Orion Genomics)
7.3.2 Pipeline of Prognostic Tools for Prostate Cancer
7.3.3 Lung Cancer
7.3.3.1 Lung Cancer Screening Test (Orion Genomics)
7.3.3.2 ConfirmMDx and InformMDx (MDxHealth)
7.3.4 The Future of Bladder Cancer Testing
7.3.4.1 Bladder Cancer Screening Test (Orion Genomics)
7.3.5 Other Cancer Tests Pipeline 2013
7.3.5.1 Pancreatic Cancer Prognostic Test (PrognosticDx Health)
7.4 Leading Epigenetic Diagnostic Developers 2013
7.4.1Epigenomics: Multiple Tests Marketed in the EU
7.4.1.1 Positive Revenue Growth 2012-2013
7.4.2 Exact Sciences: Colorectal Cancer Screening
7.4.3 MDxHealth: Targeting the US Diagnostics Markets
7.4.3.1 Strong Revenue Growth 2009-2013
7.4.4 Orion Genomics: More than 100 Markers Have Been Discovered
7.4.5 Physician’s Choice Laboratory Services (PCLS)
7.4.6 PrognosDx Health: Developing Epigenetic Prognostics
8. Research and Product Development Strategies in Epigenetics 2014
8.1 Epigenetics Therapies, Technologies and Diagnostics Market by Disease 2014-2024
8.2 Present and Future Epigenetic Research in Cancer
8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer
8.2.2 Colorectal Cancer: More Than Two Biomarkers Established
8.2.3 Lung Cancer: Prognostic Markers
8.2.4 Prostate Cancer: The Need for Progression in Epigenetic Therapies
8.3 The Role of DNA Hypomethylation in Autoimmune Diseases
8.3.1 Lupus
8.3.2 Rheumatoid Arthritis as a Target for Drugs and Diagnostics
8.3.2.1 Ignyta: Pioneer in Epigenetic Diagnostic for Rheumatoid Arthritis
8.3.3 Prevalence of Diabetes linked to Diet and Ageing
8.4 Neurodegenerative Diseases
8.4.1 Alzheimer’s Disease: Symptoms Improved with HDAC Inhibitors
8.4.2 Huntington’s Disease: Epigenetic Drugs in Clinical Development
8.5 Neurological Disorders
8.5.1 Drug Resistance in Schizophrenia
8.5.2 Hundreds of Genetic and Epigenetic Mutations linked to Autism
8.6 New Epigenetic Therapy Targets
8.6.1 BET Proteins Targeted by Multiple Therapeutic Areas
8.6.2 Importance of DNA Hydroxymethylation
8.6.3 Sirtuins: Undergoing Limited Research
8.6.4 Histone Methyltranferase
8.6.4.1 Lysine Methyltranferase
8.6.4.2 Domainex: Development of HMT Inhibitor
8.6.4.3 Protein Arginine Methyltransferases: The Need for Improved Potency
8.6.4.4 Lysine Demethylases: Potential Cancer Treatment Target
9. Epigenetic Therapies, Diagnostics and Related Technologies: Industry and Market Trends 2014-2024
9.1 Epigenetic Therapies, Technologies and Diagnostics: Strengths and Weaknesses 2014-2024
9.1.1 Understanding Epigenetic Markers and Mechanisms
9.1.2 Specificity of Marketed Epigenetic Therapies
9.2 Epigenetics Therapies, Technologies and Diagnostics Market Opportunities and Threats 2014-2024
9.2.1 The Important Role of Translational Research
9.2.2 Development of Companion Diagnostics in Conjunction with Therapies
9.2.3 Rich Therapeutic and Diagnostic Pipelines
9.2.4 Combination Therapy with Epigenetic Drugs Show Promise
9.2.5 Epigenetic Drugs to Succeed Drug Resistance
9.2.6 Therapy Target Scope besides HDAC and DNMT Inhibition
9.3 Epigenetics Therapies, Technologies and Diagnostics: STEP Analysis 2014-2024
9.4 Social Factors Affecting Epigenetic Product Development
9.4.1 The Influence of Environment
9.4.2 The Role of Epigenetics in Ageing and Diseases
9.4.2.1 Increasing Prevalence of Global Disease to Drive Epigenetics Market Growth
9.4.3 Targeting Orphan Diseases and Patient Subpopulations
9.4.4 Use of Epigenetics in Personalised and Stratified Medicine
9.5 Advancing Epigenetic Technologies to Support Epigenetic Research
9.5.1 NGS: Improving the Quality of Epigenetic Research
9.5.2 Epigenetics to Help Drive Stem Cell Research Development
9.5.3 Complementary and Competing Forces
9.5.3.1 Genomics
9.5.3.2 Proteomics
9.5.3.3 Metabolomics
9.6 Economic Factors
9.6.1 Recent Developments Helped Reduce Costs in Epigenetic Research
9.6.2 Importance of Big Pharma in Epigenetic Markets 2014-2024
9.6.2.1 Pfizer
9.6.2.2 Novartis
9.6.2.3 GSK: Part of Multiple Agreements in Epigenetics
9.6.3 Valuable Licensing Deals in Epigenetics
9.6.4 Epigenetic Business Models
9.7 Political Issues
9.7.1 Ethics in Epigenetic Research
9.7.2 Global Collaboration to Expedite Market Growth
9.7.2.1 Structural Genome Consortium
9.7.2.2 Roadmap Epigenomics Project (NIH)
9.7.2.3 International Human Epigenome Consortium
9.7.2.4 Blueprint Project
10. Research Interview
10.1 Interview with Dr Eric Marcotte, Strategic Lead, Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC)
10.1.1 Canadian Institute of Health Research: Interest in Epigenetics
10.1.2 Canadian Epigenetic Therapy Market
10.1.3 Prominent Epigenetic Therapeutic Areas in the Future
10.1.4 Promising New Epigenetic Therapy and Diagnostics
10.1.5 Future of Canadian Epigenetics Market
10.1.6 CIHR and JST Partnership Outcome
11. Conclusions from the Research and Analysis
11.1 Therapies Submarket Accounts for Most of the Epigenetic Market Revenues in 2013
11.2 Growth Expected in All Submarkets of the Epigenetic Market 2014-2024
11.2.1 Developed National Pharma Markets to Lead, 2014-2024
11.3 Many Opportunities Exist in the Epigenetics Industry and Market
【レポート販売概要】
■ タイトル：世界におけるエピジェネティクスの研究開発、治療薬、診断製品市場■ 英文：Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024
■ 発行日：2014年6月
■ 調査会社：visiongain
■ 商品コード：VISG409050
■ 調査対象地域：グローバル
- 世界のスマート/インテリジェントセンサ市場（2013 – 2020）The term smart sensor was coined in the mid-1980s, and since then several devices such as accelerometer, optical sensor, infrared detector, integrated multisensor and so on are called as smart sensors. The intelligence required by such devices is available from microcontroller unit (MCU), digital signal processor (DSP), and Application-Specific ntegrated circuit (ASIC) technologies developed by se …
- 世界のコンテナ・ユニット/コンテナ船市場2014■Overview of global container fleet Incorporating an Executive summary, these initial pages of analysis are some of the most detailed available from any source in the market today, relating directly to the container equipment fleet on a global scale. Key areas covered: • Development of the world container fleet by operating category from End-2008 to End-2013 (Teu, Unit, CEU, Cost) • World containe …
- 世界の主要なジェネリック医薬品メーカー分析Generic Drug Producers – Discover Top Companies’ Revenue Prospects Now, Benefiting Your Influence What does the future hold for manufacturers and sellers of generic medicines? Visiongain’s new report shows you leading companies’ prospects to 2025. That study lets you discover results, trends, opportunities and revenue forecasts, helping you stay ahead in knowledge. For leading producers and market …
- 乳房インプラントの世界市場：シリコン製人工乳房、食塩水人工乳房、乳房増大術、乳房再建術About Breast implant Breast implant is an artificial prosthesis made up of a silicone outer shell filled with saline and silicone gel. The breast implant procedure involves reconstruction to improve symmetry after mastectomy or other damages to the breast or enlarging the breasts for cosmetic reasons. Breast reconstruction requires tissue expanders, which helps in the expansion of breast muscles a …
- 超音波診断装置の世界市場2019-2023About this market The reliability of power generation equipment is essential as the failure of systems might adversely affect the Mole power network infrastructure and pose serious safety risks. Ultrasonic testing is used for inspecting power generation infrastructures such as boilers, turbines, compressors: pipelines, tanks, and storage vessels. Power demand has been growing globally, both as a r …
- 自動車用シリコンの世界市場分析：製品別（エラストマー、接着剤･シーラント、樹脂）、用途別（内装・外装部品、エンジン･ドライブトレインシステム、サスペンションシステム、電気系統）、地域別、セグメント予測、2014-2025The global automotive silicones market is expected to reach USD 5.84 billion by 2025, according to a new report by Grand View Research, Inc. The growing awareness about lightweight materials used in automotive production is expected to drive the demand for silicones. Automotive silicones are being used in a host of applications on account of their favorable properties such as resistance to corrosi …
- アメリカの仮想・遠隔実験室市場2016-2020About the Virtual and Remote Laboratories Market Virtual laboratories are set up on an online platform and are used to create simulation of a science process or explanation of a subject. Advanced computer languages, such as MatLab and LabView, are used to develop these laboratories. They offer anywhere, anytime access to experiments and are designed for a specific subject or a course. Through this …
- 世界の送電ケーブル及びワイヤー市場展開シナリオGlobal Transmission Cable and Wire Market Scenario Summary Increasing power demand due to increase in population and urbanization is leading to huge investments in power generation sector and creating the need for transmission cables to transmit it to end users. Moreover, Overhead transmission cables especially in developed countries are old and inefficient which needs to be replaced. This would c …
- Eastern American Energy Corporation：石油・ガスの開発・生産動向及びコスト分析- Q1, 2013Eastern American Energy Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary Eastern American Energy Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The r …
- 世界の脱塩（淡水化）市場動向：Global Desalination Market 2013-2023The Global Desalination Market 2013-2023 is GMR Data’s latest utility report. Primary drivers of the desalination market are increased urbanisation / industrialisation, water scarcity and inadequate or under maintained water infrastructure. The Global Desalination Market 2013-2023 report analyses how this important market will develop over the next ten years. The report quantifies the market in te …
- Koch Industries, Inc.：石油・ガスバリューチェーン分析レポート2013Koch Industries, Inc. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Koch Industries, Inc." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Koch Industries, Inc.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report e …
- 世界における小型自動車用シート市場（2008-2028）This latest just-auto report edition offers a global review of the OE seating sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE seating market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategies and prospects Marke …
- 静電容量式タッチパネルの世界市場2015-2019Capacitive screen displays rely on the electrical properties of the human body to detect touches. These displays can be controlled with very light touches and generally cannot be used with a mechanical stylus or a gloved hand. The global market for capacitive touchscreens is positively influenced by factors like the growing smartphone and tablet market and is expected to post a healthy market grow …
- ポリアルキレングリコールの世界市場2018-2022About Polyalkylene Glycol Polyalkylene glycol is formed by the reaction of an alcohol with one or more alkylene oxides such as propylene oxide and ethylene oxide.· Polyalkylene glycol is divided into two different product types: Polypropylene glycol and polyethylene glycol. It is used in various applications such as PU foams, lubricants, personal care, pharmaceuticals, and others in regions such a …
- 高圧電線及び付属品の世界市場：地下ケーブル、海底ケーブルThis report estimates the high voltage cables & accessories market, in terms of $Million. The market has been segmented into type of use (overhead, underground, and submarine), products for overhead, underground, and submarine types of usage, and region (Asia-Pacific, Europe, North America, Latin America, and the Middle East & Africa). The high voltage cables & accessories market is majorly led by …
